Skip to main content
SpringerLink
Log in

Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The combination of Cis-dichlorodiammineplatinum (II) (CisDDPt) + 5-Fluorouracil (5-FU) was compared with two CisDDPt analogues + 5-FU [Iproplatin (CHIP) + 5-FU and Carboplatin (CBDCA) + 5-FU] for relative efficacy against advanced stage squamous cell lung tumors (LC-12) in Balb/c mice. At equitoxic dosages, the numbers of regressions and cures were similar for the three combinations (5-FU/CISDDPt 2/10 PR's, 2/10 CR's, 2/10 cures; 5-FU/CBDCA 1/10 PR's, 5/10 CR's, 3/10 cures; 5-FU/CHIP 1/10 PR's, 3/10 CR's, 3/10 cures). The tumor growth delay among the mice not cured was slightly superior in the 5-FU/ CisDDPt regimen. All the agents were active singly against this tumor model. Based on these results, the substitution of CBDCA or CHIP for CisDDPt in a FU regimen did not offer a cytotoxic advantage. Because of different dose limiting toxicities for the platinum compounds the possibility exists that these analogues could be used in drug combinations in substitution for CisDDPt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosenberg B, Van Camp L, Trosko JE, et al.: Platinum compounds: A New Class of Potent Antitumor Agents. Nature 222:385–386, 1969

    Google Scholar 

  2. Woodman RJ, Sirica AE, Gang M, Kline I, Venditti JM: The enhanced therapeutic effect of cis-platinum (II) diammine dichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxo-piperazine-1-yl) propane or several other antitumor agents. Chemotherapy 18:169–183, 1973

    Google Scholar 

  3. Gale GR, Atkins LM, Meischen SJ, Smith AB, Walker EM: Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents. Cancer Treat Rep 61:445–450, 1977

    Google Scholar 

  4. Loehrer PJ, Einhorn LH: Cisplatin. Ann of Int Med 100:704–713, 1984

    Google Scholar 

  5. Rosenberg B. Fundamental studies with cisplatin. Cancer 55:2303–2316, 1985

    Google Scholar 

  6. Einhorn LH, Donohue JP: Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Int Med 87:293–298, 1977

    Google Scholar 

  7. Al-Sarraf M: Chemotherapy strategies in squamous cell carcinoma of the head and neck — CRC Crit Rev Oncol Hematol 1:323–355, 1984

    Google Scholar 

  8. Kish J, Drelichman A, Jacobs J, et al.: Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 66:471–474, 1982

    Google Scholar 

  9. Kish JA, Weaver A, Jacobs J, et al.: Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 53:1819–1824, 1984

    Google Scholar 

  10. Leichman L, Seydel HG, Steiger Z: Pre-operative adjuvant therapy for squamous cell cancer of the esophagus. (Abstr) Proc Am Soc Clin Oncol 3:575, 1984

    Google Scholar 

  11. Rooney M, Kish JA, Jacobs J, et al.: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 55:1123–1128, 1985

    Google Scholar 

  12. Al-Kourainy K, Kish JA, Ensley J, et al.: Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 59:233–238, 1987

    Google Scholar 

  13. Schabel FM, Trader MW, Laster WR, Corbett TH, Grisswold DP: Cis-dichlorodiammineplatinum II: Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459–1473, 1979

    Google Scholar 

  14. Vonhoff DD, Shilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM: Toxic effects of cisdichlorodiammineplatinum in man. Cancer Treat Rep 63:1527–1531, 1979

    Google Scholar 

  15. Lee FH, Canetta R, Issell BF, Lenoz L: New platinum complexes in clinical trial. Cancer Treatment Review 10:39–51, 1983

    Google Scholar 

  16. Kish J, Ensley J, Al-Sarraf M, Vonhoff DD, Schuller D: Activity of CHIP and CBDCA (platinum analogs) in recurrent epidermoid cancer of the head and neck — randomized Phase II trial of WSU and SWOG. (Abstr) Proc Am Soc Clin Oncol 4:504, 1985

    Google Scholar 

  17. Smith WE, Yazdi E, Miller L: Carcinogenesis in pulmonary epithelia in mice on different levels of vitamin A. Environ Res 5:152–163, 1972

    Google Scholar 

  18. Corbett TH, Griswold DP, Jr, Roberts BJ, Peckham JC, Schabel FM, Jr: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40:2660–2680, 1977

    Google Scholar 

  19. Corbett TH, Criswold DP, Jr, Roberts BJ, Peckham JC, Schabel FM, Jr: Biology and therapeutic response of a mouse mammary adenocarcinoma (16/c) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62:1471–1488, 1978

    Google Scholar 

  20. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP, Jr, Schabel FM, Jr: Toxicity and anticancer activity of a new triazine antifolate (NSC-127755). Cancer Res 42:1707–1715, 1982

    Google Scholar 

  21. Corbett TH, Criswold DP, Jr, Wolyert MK, Venditti JM, Schabel FM, Jr: Design and evaluation of combination chemotherapy trials in experimental animal tumor systems. Cancer Treat Rep 63:5:799–801, 1979

    Google Scholar 

  22. Venditti JM, Goldin A: Drug synergism in antineoplastic chemotherapy. Adv. Chemother 1:397–498, 1964

    Google Scholar 

  23. Schabel FM, Jr: New experimental drug combinations with potential clinical utility. Biochem Pharmacol 2(S):163–176, 1974

    Google Scholar 

  24. Drewinko B, Corry P, Bergerat JP, Barlogie B: The lethal activity of platinum compounds in combination with pyrimidine derivatives. In: A.W. Prestayko, S.T. Crooke, S.K. Carter (eds). Cis-Platin: Current Status and New Developments. 37–55 New York: Academic Press 1980

    Google Scholar 

  25. Rose WC, Schurig JE: Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev (Suppl A): 1–19, 1985

  26. Schabel FM, Jr, Skipper HE, Trader MW, Laster WR, Jr, Griswold DP, Jr, Corbett TH: Establishment of cross resistance profiles for new agents. Cancer Treat Rep 67:905–922, 1983 (Corrected tables cited in Cancer Treat Rep 68: 453–459, 1984)

    Google Scholar 

  27. Harrap KR, Jones M, Wilkinson CR, Clink HM, Sparrow S, Mitchley BCV, Clarke S, Veasey A: Antitumor, toxic and biochemical properties of Cisplatin and eight other platinum complexes. In: A.W. Prestayko, S.T. Crooke, S.K. Carter (eds) Cisplatin, Currents Status and New Developments, pp. 37–55. Academic Press, N.Y., 1980

    Google Scholar 

  28. Schweitzer VG, Rarey KE, Dolan DF et al: Ototoxicity of cisplatin vs platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngol Head Neck Surg 94:458–470, 1986

    Google Scholar 

  29. Ensley J, Maciorowski Z, Crissman J et al.: Comparison of nuclei released and fixed with acetic acid and whole cell suspensions produced by combination enzymatic dissociation and ethanol fixation in a well differentiated murine squamous cell carcinoma of the lung (LC-12) in preparation for cellular DNA analysis by flow cytometry. (Abstr) Proc Am Assoc Cancer Res 25:33, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Department of Internal Medicine, Division of Hematology and Oncology, Division of Hematology and Oncology, Wayne State University School of Medicine and Harper-Grace Hospitals, 48201, Detroit, MI, USA

    Efstathios Tapazoglou, Lisa Polin, Thomas H. Corbett & Muhyi Al-Sarraf

Authors
  1. Efstathios Tapazoglou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Polin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas H. Corbett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Muhyi Al-Sarraf
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tapazoglou, E., Polin, L., Corbett, T.H. et al. Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations. Invest New Drugs 6, 259–264 (1988). https://doi.org/10.1007/BF00173643

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00173643

Key words

Search

Navigation